Plus   Neg

Galmed Pharmaceuticals Ltd. (GLMD) Has Soared To A New High On Study Results

Galmed Pharmaceuticals Ltd. (GLMD) reported results from its Phase 2 study of Aramchol 600mg Tuesday morning. The study demonstrated a statistically significant reduction in liver fat.

Galmed Pharmaceuticals has gapped open dramatically higher this morning and is now up 18.11 at $25.11 on the highest volume of the year. The stock has soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT